Lilly’s Pegilodecakin Fails Pancreatic Cancer Test

Asset came from $1.6bn Armo buy

 
• By Kevin Grogan
Forest_Tree
Sequoia falls but Lilly hopes Cypress studies fare better • Source: Shutterstock

More from Clinical Trials

More from R&D